Tag:
Dificid
Latest Headlines
Latest Headlines
Optimer ousts chairman, top execs over a grant of shares in affiliate
Hank McKinnell has a new biopharma mess to sort out.
Optimer inks $90M C. difficile drug pact with Astellas
Optimer is pocketing a $20 million up-front payment on a new commercial pact for its treatment for C. difficile.
Will hospitals pay premium for Optimer's Dificid?
Will hospitals pay more for Optimer Pharmaceuticals' new antibiotic Dificid? That's the question, now that the FDA has given its blessing to the drug, which is the first new treatment in 25 years for
UPDATED: FDA gives Optimer key antibiotic approval
There's going to be a lot of backslapping at barbeques in San Diego this weekend. The FDA sent out word this afternoon that it's approved San Diego-based Optimer Pharmaceuticals' ($OPTR) antibiotic
Stage set for Optimer's weapon against deadly infections
As we put this edition of FierceBiotech to bed, there was still no word from the FDA on potential approval of Optimer Pharmaceuticals' antibiotic fidaxomicin (Dificid). The PDUFA date of May 30 falls
Optimer readies antibiotic campaign after winning FDA panel vote
Optimer Pharmaceuticals won the unanimous support of an FDA panel of experts for its new antibiotic fidaxomicin and can now march into the agency with a solid endorsement on safety and efficacy. But
